The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis

BioDrugs · Published 2026-01-14 · DOI 10.1007/s40259-025-00762-w

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s40259-025-00762-w

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• The OX40-OX40L Co-Stimulatory Pathway as a Shared Driver of Immune Persistence in Skin and Airway Inflammation · Clinical Reviews in Allergy and Immunology · 2026 · Cites or is cited by this article
• mRNA Vaccines for Influenza: Hope for a Universal Vaccine? · BioDrugs · 2026 · Same journal
• Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability · BioDrugs · 2025 · Same journal
• Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential · BioDrugs · 2025 · Same journal
• Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics · BioDrugs · 2026 · Same journal
• Interleukin-23 Inhibitors in Inflammatory Bowel Disease · BioDrugs · 2026 · Same journal
• Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline · BioDrugs · 2025 · Same journal
• Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan’s C-CAT Registry · BioDrugs · 2026 · Same journal
• Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review · BioDrugs · 2025 · Same journal
• Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study · BioDrugs · 2025 · Same journal